ACS 化学神经科学分子特写：RG1678。
ACS chemical neuroscience molecule spotlight on RG1678.
机构信息
Department of Pharmacology and Chemistry, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University , Nashville, Tennessee 37232-6600, USA.
出版信息
ACS Chem Neurosci. 2011 Dec 21;2(12):685-6. doi: 10.1021/cn200108z.
Abstract
RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.
摘要
RG1678 是一种甘氨酸转运蛋白 1 抑制剂，目前正在进行治疗精神分裂症阴性症状的 III 期临床试验，由罗氏（与中外制药合作开发）研发。最近的 II 期数据表明，当 RG1678 与第二代抗精神病药物联合使用时，可有效减轻阴性症状。
相似文献
1
ACS chemical neuroscience molecule spotlight on RG1678.
ACS Chem Neurosci. 2011 Dec 21;2(12):685-6. doi: 10.1021/cn200108z.
2
The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey.
Psychopharmacology (Berl). 2014 Feb;231(3):511-9. doi: 10.1007/s00213-013-3260-0. Epub 2013 Sep 20.
3
Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.
Chimia (Aarau). 2018 Aug 22;72(7):477-484. doi: 10.2533/chimia.2018.477.
4
Schizophrenia drug gets negative results for negative symptoms.
Nat Rev Drug Discov. 2014 Apr;13(4):244-5. doi: 10.1038/nrd4294.
5
Glycine transport inhibitors in the treatment of schizophrenia.
Handb Exp Pharmacol. 2012(213):367-99. doi: 10.1007/978-3-642-25758-2_12.
6
Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.
J Med Chem. 2010 Jun 24;53(12):4603-14. doi: 10.1021/jm100210p.
7
Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
JAMA Psychiatry. 2014 Jun;71(6):637-46. doi: 10.1001/jamapsychiatry.2014.163.
8
Therapeutics: Negative feedback.
Nature. 2014 Apr 3;508(7494):S10-1. doi: 10.1038/508S10a.
9
Structural insights into the inhibition of glycine reuptake.
Nature. 2021 Mar;591(7851):677-681. doi: 10.1038/s41586-021-03274-z. Epub 2021 Mar 3.
10
Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.
Neuropharmacology. 2012 Feb;62(2):1152-61. doi: 10.1016/j.neuropharm.2011.11.008. Epub 2011 Nov 27.
引用本文的文献
1
The Dysregulated MAD in Mad: A Neuro-theranostic Approach Through the Induction of Autophagic Biomarkers LC3B-II and ATG.
Mol Neurobiol. 2023 Sep;60(9):5214-5236. doi: 10.1007/s12035-023-03402-y. Epub 2023 Jun 5.
2
Schizophrenia: synthetic strategies and recent advances in drug design.
Medchemcomm. 2018 Mar 16;9(5):759-782. doi: 10.1039/c7md00448f. eCollection 2018 May 1.
3
Glycine transporter 1 is a target for the treatment of epilepsy.
Neuropharmacology. 2015 Dec;99:554-65. doi: 10.1016/j.neuropharm.2015.08.031. Epub 2015 Aug 21.
4
Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo.
Pharmacol Res Perspect. 2013 Oct;1(1):e00007. doi: 10.1002/prp2.7. Epub 2013 Oct 1.
5
Two grams of sarcosine in schizophrenia - is it too much? A potential role of glutamate-serotonin interaction.
Neuropsychiatr Dis Treat. 2014 Feb 4;10:263-6. doi: 10.2147/NDT.S54024. eCollection 2014.
6
Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.
Discov Med. 2012 Nov;14(78):335-43.
7
Chiral proton catalysis of secondary nitroalkane additions to azomethine: synthesis of a potent GlyT1 inhibitor.
Chem Commun (Camb). 2012 Jun 7;48(45):5578-80. doi: 10.1039/c2cc32225k. Epub 2012 Apr 30.
本文引用的文献
1
Glycine transport inhibitors for the treatment of schizophrenia.
Open Med Chem J. 2010 May 27;4:10-9. doi: 10.2174/1874104501004010010.
2
Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.
J Med Chem. 2010 Jun 24;53(12):4603-14. doi: 10.1021/jm100210p.
3
The economic burden of schizophrenia in the United States in 2002.
J Clin Psychiatry. 2005 Sep;66(9):1122-9. doi: 10.4088/jcp.v66n0906.
4
Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.
Pharmacol Rev. 1998 Dec;50(4):597-664.
Zotero 插件